The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
The primary goal of the collaboration is joint research into trending and next-generation molecules
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Subscribe To Our Newsletter & Stay Updated
